Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasm Metastasis 8Colorectal Neoplasms 7Lung Neoplasms 6Prostatic Neoplasms 5Melanoma 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Fallopian Tube Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Meningioma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Glioblastoma 2Gastrointestinal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2

Interventions

Docetaxel 3pazopanib 2Trabectedin 2Doxorubicin 2toripalimab 1temsirolimus 1sapanisertib 1nilotinib 1liposomal doxorubicin 1lenvatinib 1lentiviral minigene vaccine of COVID-19 coronavirus 1eribulin 1cemiplimab 1avelumab 1abemaciclib 1Sunitinib 1Specimen Handling 1Radiotherapy 1Nivolumab 1Methotrexate 1Imatinib Mesylate 1Ifosfamide 1HhAntag691 1Gemcitabine 1Epirubicin 1Dacarbazine 1Cisplatin 1Biopsy 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leiomyosarcoma × Specimen Handling × Clear all
NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡